Literature DB >> 14658716

Initial and long-term efficacy of a lipid emulsion of amphotericin B desoxycholate in the management of canine leishmaniasis.

Oscar Cortadellas1.   

Abstract

Sixteen dogs in which canine leishmaniasis (CL) was diagnosed by positive identification of Leishmania amastigotes in bone marrow samples were treated with a mixture of amphotericin B (AmB) desoxycholate in soybean oil. To prevent the toxicity of AmB, dogs were pretreated with saline (50 mL/kg) and mannitol (2 g/kg). Dogs were treated twice weekly with an increasing dosage of amphotericin (0.8-2.5 mg/kg) for between 8 and 10 sessions. Transient adverse effects (anorexia, vomiting, or both) appeared in 81% of the dogs during therapy. At the end of the course, all dogs were clinically cured, with no parasites observed in bone marrow smears. Six of the 16 dogs (38%) were positive by polymerase chain reaction (PCR) in bone marrow samples at some stage of their follow-up, but only 2 were positive at the first test after treatment, which was performed within 5 months after the end of the therapy. The other 4 dogs were initially negative and became PCR-positive at subsequent examinations. Three of these 6 dogs also experienced a clinical relapse. Four dogs had at least 3 consecutive negative PCR tests during a minimum period of 18 months and were clinically cured. The results of the present study indicate that despite having a high initial effectiveness in the treatment of CL, relapses can occur with the described protocol. Also, a single negative PCR result in a recently treated dog cannot be interpreted as a complete cure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14658716     DOI: 10.1111/j.1939-1676.2003.tb02518.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  5 in total

1.  Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.

Authors:  Leonid Kagan; Pavel Gershkovich; Kishor M Wasan; Donald E Mager
Journal:  AAPS J       Date:  2011-03-23       Impact factor: 4.009

2.  Leishmania infantum isolates exhibit high infectivity and reduced susceptibility to amphotericin B.

Authors:  Paula Faral-Tello; Gonzalo Greif; Dinora Satragno; Yester Basmadjián; Carlos Robello
Journal:  RSC Med Chem       Date:  2020-07-06

Review 3.  Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Wendel Coura-Vital; Henrique Gama Ker; Nádia das Dores Moreira; Juliana Vitoriano-Souza; Rodolfo Cordeiro Giunchetti; Cláudia Martins Carneiro; Alexandre Barbosa Reis
Journal:  Front Immunol       Date:  2014-06-13       Impact factor: 7.561

4.  Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease.

Authors:  Carmen Pineda; Escolastico Aguilera-Tejero; Maria C Morales; Silvia Belinchon-Lorenzo; Luis C Gomez-Nieto; Pablo Garcia; Julio M Martinez-Moreno; Maria E Rodriguez-Ortiz; Ignacio Lopez
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

Review 5.  Infectious hepatopathies in dogs and cats.

Authors:  Shawn Kearns
Journal:  Top Companion Anim Med       Date:  2009-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.